KBI Biopharma Executive and Leadership Team

Shardene Basisa, the Chief Executive Officer at KBI Biopharma, directs the overarching strategy and vision for the organization. This leadership role involves guiding the company's mission to drive breakthroughs in biopharmaceutical development and manufacturing, ensuring positive impacts on patient lives worldwide. Basisa oversees the integration of all departmental functions, aligning them with the company's growth objectives and market position as a next-generation CDMO. The Chief Executive Officer's responsibilities extend to fostering a culture of innovation and operational excellence across all global sites. By setting strategic priorities and ensuring robust execution, Shardene Basisa champions the company's commitment to advancing therapeutic solutions and solidifying its reputation in the biopharmaceutical industry. This executive leadership ensures KBI Biopharma consistently meets and exceeds client expectations in delivering high-quality development and manufacturing services.

Katherine Wolf, the Chief Financial Officer at KBI Biopharma, directs all financial planning, management, and reporting activities. This executive function is vital for sustaining the company's mission of driving biopharmaceutical breakthroughs and ensuring long-term financial health. Wolf oversees budgeting, forecasting, capital allocation, and investor relations, providing strategic financial guidance to support KBI Biopharma's growth as a leading CDMO. The Chief Financial Officer's responsibilities include managing financial risks, optimizing resource utilization, and ensuring compliance with all financial regulations. By maintaining fiscal discipline and identifying strategic investment opportunities, Katherine Wolf enables the company to expand its capabilities and reach more patients globally. This financial oversight is crucial for supporting research and development initiatives and ensuring the sustainable delivery of advanced manufacturing services.

Peter Carbone, the Chief Operating Officer at KBI Biopharma, manages the day-to-day operational execution and efficiency of the company's development and manufacturing processes. This critical role ensures that KBI Biopharma's CDMO services are delivered with the highest standards of quality and reliability, directly supporting the mission of impacting patient lives. Carbone oversees global manufacturing operations, supply chain management, and process optimization initiatives. The Chief Operating Officer's focus is on scaling operations to meet increasing demand while maintaining stringent regulatory compliance and driving continuous improvement across all facilities. By streamlining workflows and implementing best practices, Peter Carbone enhances the company's capacity to accelerate biopharmaceutical breakthroughs for clients. This leadership ensures seamless integration of new technologies and methodologies, reinforcing KBI Biopharma's position as a leader in the biopharmaceutical manufacturing sector.

Toshihiro Ogawa, the President, Kbi Biopharma (Japan) at KBI Biopharma, spearheads the strategic direction and operational management for the company's activities within Japan. This leadership position is key to expanding KBI Biopharma's global reach and impact in biopharmaceutical development and manufacturing. Ogawa oversees regional business development, client relations, and the execution of manufacturing services tailored to the Japanese market. The President, Kbi Biopharma (Japan)'s responsibilities include ensuring alignment with global corporate objectives while adapting strategies to local market dynamics and regulatory landscapes. By driving growth and operational excellence in Japan, Toshihiro Ogawa contributes significantly to KBI Biopharma's overall mission of positively impacting patient lives worldwide. This executive's focus ensures robust service delivery and strengthens the company's presence in a vital biopharmaceutical hub.

Debra Bruneau, the Chief People Officer at KBI Biopharma, leads human capital strategy and organizational development to support the company's mission of advancing biopharmaceutical manufacturing. This role is essential for cultivating a high-performing workforce dedicated to innovation and patient well-being. Bruneau oversees talent acquisition, employee engagement, compensation and benefits, and learning and development programs across all KBI Biopharma locations. The Chief People Officer's focus is on building a strong organizational culture that attracts, retains, and develops top talent in the biopharmaceutical industry. By championing employee growth and fostering an inclusive environment, Debra Bruneau ensures that KBI Biopharma has the skilled personnel necessary to drive breakthroughs and deliver exceptional CDMO services. This strategic approach to people management underpins the company's operational success and its commitment to positively impacting patient lives.